Needham Reiterates Buy Rating on Revolution Medicines, Keeps $275 Target
Needham reiterated its Buy rating and $275 price target on Revolution Medicines. The target implies 42.1% upside from the October 14 close of $193.52.
Needham reiterated its Buy rating and $275 price target on Revolution Medicines. The target implies 42.1% upside from the October 14 close of $193.52.